You are here

SBIR Phase II: Electronic Pills for Medication Compliance

Award Information
Agency: National Science Foundation
Branch: N/A
Contract: 0646491
Agency Tracking Number: 0539751
Amount: $500,000.00
Phase: Phase II
Program: SBIR
Solicitation Topic Code: EL
Solicitation Number: NSF 05-557
Timeline
Solicitation Year: 2005
Award Year: 2007
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
4817 SW 34th Street, Suite 4 6745 HOLLISTER AVENUE
Gainesville, FL 32608
United States
DUNS: 176698624
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 Neil Euliano
 PhD
 (352) 378-4899
 neil@conveng.com
Business Contact
 Neil Euliano
Title: PhD
Phone: (352) 378-4899
Email: neil@conveng.com
Research Institution
N/A
Abstract

This Small Business Innovation Research (SBIR) Phase II research project shall evaluate the use of electronic pills for medication compliance monitoring. Medication compliance monitoring is critical in pharmaceutical clinical trials, geriatrics, and mental health /addiction medicine. The only proven method for accurately determining medication compliance is directly observed therapy where personnel are present during ingestion by the patient. This technique is labor intensive, but effective. In vivo biotelemetry and monitoring is a rapidly growing field that may provide the next critical breakthrough in medical monitoring. This research will focus on the development of these two solutions, namely a UHF resorbable antenna printed on the outside of an existing capsule or pill with or without a chip designed to improve signal to noise ratio and provide ID capability. The antennas will be printed with standard ink-jet technology. A handheld RF communication device will sense the presence of the pill in the GI tract and positively confirm that the medication regimen
was followed appropriately. Electronic pill technology and R&D will help expand the rapidly growing field of in vivo telemetry. The development of biodegradable low power miniature circuits will be an important step to future bio-implantable chips and sensors. Additionally, the field of medication compliance is tremendously important in many areas of medicine. In particular, better compliance monitoring can greatly reduce the costs associated with FDA approval of pharmaceuticals as well as provide dramatically improved data for accurate determination of low probability side effects.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government